menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Severe Asthma: An Exploratory Study on Mucus Plugging

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Join us as we review the data in mucus plugging in SA with Dr. Charles Turck and Professor Arnaud Bourdin. 

  • Sponsored by

  • Overview

    Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdin. Professor Bourdin is the Head of Pulmonology at the Arnaud de Villeneuve Hospital in Montpellier, France.

    TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.
    ©2024 Amgen and AstraZeneca. All rights reserved. US-83499 Last Updated 1/24

  • INDICATION

    TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

    TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.

  • IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS
    Known hypersensitivity to tezepelumab-ekko or excipients.

    WARNINGS AND PRECAUTIONS
    Hypersensitivity Reactions
    Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

    Acute Asthma Symptoms or Deteriorating Disease
    TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.

    Abrupt Reduction of Corticosteroid Dosage
    Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

    Parasitic (Helminth) Infection
    It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

    Live Attenuated Vaccines
    The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.

    ADVERSE REACTIONS
    The most common adverse reactions (incidence ≥3%) are pharyngitis, arthralgia, and back pain.

    USE IN SPECIFIC POPULATIONS
    There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

    You may report side effects related to AstraZeneca products (opens new window)

    Please see full Prescribing Information, including Patient Information and Instructions for Use, or at TezspireHCP.com.

Schedule30 May 2024